Castle Biosciences, Inc. (CSTL)

NASDAQ: CSTL · IEX Real-Time Price · USD
26.82
+0.11 (0.41%)
At close: Feb 7, 2023, 4:00 PM
26.29
-0.53 (-1.98%)
After-hours: Feb 7, 2023, 5:00 PM EST
0.41%
Market Cap 706.75M
Revenue (ttm) 123.74M
Net Income (ttm) -52.95M
Shares Out 26.35M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 115,130
Open 27.00
Previous Close 26.71
Day's Range 25.95 - 27.10
52-Week Range 15.58 - 48.40
Beta 1.00
Analysts Buy
Price Target 50.49 (+88.26%)
Earnings Date Feb 27, 2023

About CSTL

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test... [Read more]

Sector Healthcare
IPO Date Jul 25, 2019
Employees 517
Stock Exchange NASDAQ
Ticker Symbol CSTL
Full Company Profile

Financial Performance

In 2021, CSTL's revenue was $94.09 million, an increase of 50.18% compared to the previous year's $62.65 million. Losses were -$31.29 million, 204.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for CSTL stock is "Buy." The 12-month stock price forecast is $50.49, which is an increase of 88.26% from the latest price.

Price Target
$50.49
(88.26% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023.

8 hours ago - Business Wire

Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a 2023...

6 days ago - Business Wire

Castle Biosciences' Medical Director to Present at the Precision Medicine World Conference 2023

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company's medical ...

2 weeks ago - Business Wire

Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences' Skin Cancer Test Portfolio

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting th...

3 weeks ago - Business Wire

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited prelimina...

1 month ago - Business Wire

Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Accreditation Comm...

2 months ago - Business Wire

Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study ...

2 months ago - Business Wire

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing how the Co...

3 months ago - Business Wire

Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been named a Houston Chronicle Top Work...

3 months ago - Business Wire

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -10% and 7.73%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto...

3 months ago - Zacks Investment Research

Castle Biosciences Announces Third Quarter 2022 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the...

3 months ago - Business Wire

Castle Biosciences to Present at Upcoming Investor Conferences

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that the Company's executive management is scheduled to present a company overview at three investor conferences later this month.

3 months ago - Business Wire

Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxSCC--Castle announced the publication of real-world data showing that DecisionDx-SCC test results can lead to changes in patient management str...

3 months ago - Business Wire

Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) Program

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data as part of the Company's ongoing collaboration with the NCI's SEER Program.

3 months ago - Business Wire

New Data Demonstrate that the Utilization of TissueCypher® Barrett's Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett's Esophagus over the Standard of Care Alone

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Data shows that using TissueCypher results can significantly improve management decisions for Barrett's esophagus patients with low-gra...

3 months ago - Business Wire

Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data showing that DecisionDx-SCC test results positively impacted patient management in over 80% of a Medicare-eligible cohort...

3 months ago - Business Wire

New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data showing DecisionDx®-Melanoma test results influenced 85% of clinicians' decisions regarding the SLNB surgical procedure.

3 months ago - Business Wire

Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will release its financial results for the third quarter and nine months ended Sept.

3 months ago - Business Wire

Results from a Randomized Controlled Trial Show That TissueCypher® Barrett's Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarretsEsophagus--Castle shared new data for its TissueCypher® Barrett's Esophagus Test at the 30th United European Gastroenterology (UEG) Week.

4 months ago - Business Wire

Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced a recent poster presentation at CAP22 showcasing the performance of its diagnostic gene expression profile test, DiffDx®-Melanoma.

4 months ago - Business Wire

Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present data highlighting its portfolio of skin cancer GEP tests at the 2022 ASDS Annual Meeting.

4 months ago - Business Wire

Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a study validating the performance of DecisionDx®-Melanoma's proprietary algorithm, i31-ROR.

4 months ago - Business Wire

Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle provided a proposed framework for use of its MyPath® Melanoma and DiffDx®-Melanoma tests to help achieve personalized management plans.

4 months ago - Business Wire

Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences will present the Company's foundational guideposts and three-year financial targets during its Investor Day today.

5 months ago - Business Wire

Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AZBio--Castle Biosciences announced that it has received an AZBio Fast Lane Award from the Arizona Bioindustry Association (AZBio).

5 months ago - Business Wire